{
    "2019-12-04": [
        [
            {
                "time": "2023-10-01",
                "original_text": "Bayer and Teva Double Down on Worst M&A Deals of Decade",
                "features": {
                    "keywords": [
                        "Bayer",
                        "Teva",
                        "M&A",
                        "Worst Deals",
                        "Decade"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-01",
                "original_text": "Axsome Narcolepsy Candidate Meets Phase II Goal, Stock Up",
                "features": {
                    "keywords": [
                        "Axsome",
                        "Narcolepsy",
                        "Phase II",
                        "Candidate",
                        "Stock Up"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}